Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Citing Lack Of Infrastructure, Brakes Are Put On Allowing Phase I Trials In India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After building great expectations on allowing Phase I human studies in India, the government has now back tracked from taking any concrete decisions until the "right infrastructure" is put in place

You may also be interested in...

Powerful Parliamentary Committee Slams India’s Drug Regulator; Calls For Swift Overhaul

The committee unravels a system full of questionable practices and recommends complete overhaul of India’s drug regulator.

CROs in Asian Giants India and China Create Alliance To Conduct Clinical Trials To Keep Pace With Exploding Demand

BEIJING - In response to rapidly accelerating demand for clinical drug research across Asia, India's GVK Biosciences and China's Excel PharmaStudies are crafting an alliance to jointly conduct trials in both countries

India’s DCGI Issues Warning Letter To Wyeth, GVK Over Trial

The Drug Controller General of India issued warning letters to U.S.-based Wyeth Pharmaceutical and a clinical trial monitor for violating Indian trial rules. The CDGI said an audit of a suspended trial of a pneumococcal vaccine in India disclosed violations of protocol, standard operating procedure and good clinical practices. The monitor was GVK Biosciences. DCGI ordered the trial suspended last November after the death of an infant, which the agency said protocol dictated should not have been included in the trial. The incident, involving a trial that began in 2007 with 350 children, is the first recorded in India. (Click here for more

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts